PainRelief.com: What should readers take away from your report?

Response: Treating fibromyalgia is complicated and takes individualized plans for each patient. There are multiple approaches, and cannabis derivatives could be incorporated into such a plan. However, one must remember that the evidence is preliminary and it is still unclear which subset of patients will see benefit from this and what combination of therapies is most efficacious. Importantly, cannabis and derivatives use is not without risk, and those should be weighed against the potential benefit by healthcare providers prior to incorporating these agents as part of a treatment plan. 

PainRelief.com: What recommendations do you have for future research as a result of this work?

Response: Larger studies are required to further elucidate the therapeutic regimens, dosing, and proper patient selection.

We have no disclosures.

Citation:

Amnon A. Berger, Joseph Keefe, Ariel Winnick, Elasaf Gilbert, Jonathan P. Eskander, Cyrus Yazdi, Alan D. Kaye, Omar Viswanath, Ivan Urits,
Cannabis and cannabidiol (CBD) for the treatment of fibromyalgia,
Best Practice & Research Clinical Anaesthesiology,
Volume 34, Issue 3, 2020, Pages 617-631,

[last-modified]

The information on PainRelief.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.

Last Updated on October 29, 2020 by PainRelief.com